bezuclastinib
cogent biosciences
['apex']
today at we're presenting preclinical data at #aacr23 highlighting our precision therapy pipeline #erbb2 #fgfr2. we also announced the initiation of part 2 of our apex trial with bezuclastinib in #advsm read more here: 
Precision therapeutics for genetically defined diseases